संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

wockhardt usa llc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 2.5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

wockhardt limited - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 2.5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril maleate 2.5 mg - enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mayne pharma (usa) inc. - enalaprilat (unii: gv0o7es0r3) (enalaprilat - unii:gv0o7es0r3) - injection, solution - 1.25 mg in 1 ml - enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. in using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (see warnings ). in considering use of enalaprilat injection, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it sho

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

aurobindo pharma limited - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - trandolapril 1 mg - hypertension trandolapril tablets usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. heart failure post myocardial infarction or left-ventricular dysfunction post myocardial infarction trandolapril tablets usp are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of trandolapril to caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see clinical pharmacology - heart failure or left-ventricular dysfunction post myocardial infarction for details of the survival trial). trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ace inhibitor. do not co-administer aliskiren with trandolapril in patients with diabetes (see precautions, drug interactions ). trandolapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer trandolapril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ).  

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

rising pharma holdings, inc. - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - trandolapril 1 mg - hypertension trandolapril tablets usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. heart failure post myocardial infarction or left-ventricular dysfunction post myocardial infarction trandolapril tablets usp are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of trandolapril to caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see clinical pharmacology -heart failure or left-ventricular dysfunction post myocardial infarction for details of the survival trial). trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ace inhibitor. do not co-administer aliskiren with trandolapril in patients with diabetes (see precautions, drug interactions ). trandolapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer trandolapril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ).

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 20 mg - hypertension enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. heart failure enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failu

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

redpharm drug, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 10 mg - hypertension enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. heart failure enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failu

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

directrx - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 10 mg - hypertension enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. heart failure enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failu

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improve symptoms, increase survival, and decrease the frequency of hospitalization (see clinical pharmacology , heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤ 35 percent), enalapril maleate tablets usp decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see clinical pharmacology , heart